Clinical Research Directory
Browse clinical research sites, groups, and studies.
171 clinical studies listed.
Filters:
Tundra lists 171 Colorectal Neoplasms clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07631884
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants. The main question it aims to answer is: What is the objective response rate of Trastuzumab Rezetecan in adult patients with HER-2 expressed advanced solid tumors? Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg/kg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-20
1 state
NCT07222800
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy that is approved for colorectal cancer, can help people whose cancer has spread or returned after treatments taken before. To join the study, participants must meet the following conditions: * Be 18 years or older. * Have colorectal cancer that has spread to other parts of your body. * Be in good enough health to receive study treatment. * Should not be pregnant before starting treatment. Participants will be randomized (like flipping a coin) to one of 2 different treatment arms. The first arm (Arm A) will include the new medicine PF-08634404 in combination with chemotherapy that is approved for colorectal cancer, and the second arm (Arm B) will include an approved medicine for colorectal cancer, called Bevacizumab, in combination with chemotherapy that is approved for this type of cancer. Participants and their doctors will not know which arm they are being assigned to. Participants will receive all the study medications through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, and participants may continue receiving it if it is helping and they are not experiencing serious side effects. The medicine will be given at a clinical site, where trained medical staff will check participants during and after each treatment. * The study is expected to last approximately 33 months for each participant. * Participants will have regular visits to the study site for treatment, health checks, and tests. * After stopping treatment, participants will return for a final visit about 30 to37 days later to check their health and review any side effects. * Follow-up will continue every 12 weeks by phone or in person or by reviewing health records to check on health status and any new treatments.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-20
91 states
NCT07715903
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Background: Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump. The HAI pump is installed in the artery that goes to the liver; drugs are administered directly to the liver through this pump. But these tumors often return after treatment. Carfilzomib (CFZ) is a drug approved to treat another kind of cancer. Researchers want to find out if this drug may be helpful when administered through the HAI pump directly to the liver for people with colon, adrenal glands, or bile duct cancer that has spread to the liver. Objective: To test the safety of carfilzomib (CFZ) delivered via a hepatic artery infusion (HAI) pump directly to the liver in people with cancer in their liver. Eligibility: People aged 18 years or older with cancers of the colon, adrenal glands, or bile ducts that spread to the liver and persist after treatment. They must have a functioning hepatic artery infusion (HAI) pump in place from previous treatment of HAI pump therapy. Design: Participants will be screened. They will have a physical exam, blood tests, imaging scans, and a test of their heart function. They will also have a test to show how the blood flows through their liver: A radioactive substance will be injected into a vein, and a special camera will take pictures of the blood flow for up to 1 hour. Participants will receive the study drug for about 6 months. They will visit the clinic once a week. Their HAI pump will be filled with the drug at each visit; the drug will slowly drain from the pump into the liver. Blood tests and imaging scans will be repeated during the study. Participants will have follow-up visits 1 and 3 months after their last dose of study drug. An optional liver biopsy (tissue sample) for research purposes may be done before the study drug is given, and again (optional) within 28 days after first receiving the study drug. Individuals may participate in the study even if they do not agree to have the biopsies done. ...
Gender: All
Ages: 18 Years - 120 Years
Updated: 2026-11-20
1 state
NCT04222413
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help. It stops cancer cells from growing and spreading further and possibly shrink cancer lesions in distant organs. Objective: To find a safe dose of metarrestin and to see if this dose shrinks tumors. Eligibility: Adults age 18 and older with pancreatic cancer, breast cancer, or a solid tumor that has not been cured by standard therapies. Also, children age 12-17 with a solid tumor (other than a muscle tumor) with no standard therapy options. Design: Participants will be screened with: * blood tests * physical exam * documentation of disease confirmation or tumor biopsy * electrocardiogram to evaluate the heart * review of their medicines and their ability to do their normal activities Participants will take metarrestin by mouth until they cannot tolerate it or stop to benefit from it. They will keep a medicine diary. Participants will visit the Clinical Center. During the first month there are two brief hospital stays required with visits weekly or every other week thereafter. They will repeat some of the screening tests. They will fill out questionnaires. They will have tests of their cognitive function. They will have an electroencephalogram to record brain activity. They will have a computed tomography (CT) scan or magnetic resonance imaging (MRI). A CT is a series of X-rays of the body. An MRI uses magnets and radio waves to take pictures of the body. Adult participants may have tumor biopsies. Participants will have a follow-up visit 30 days after treatment ends. Then they will have follow-up phone calls or emails every 6 months for the rest of their life or until the study ends.
Gender: All
Ages: 12 Years - 120 Years
Updated: 2026-11-20
2 states
NCT05253651
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-20
79 states
NCT07631871
An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy
The goal of this clinical trial is to learn if Zanidatamab can treat HER2-positive advanced tumors in adults. The main question it aims to answer is: What is the objective response rate of Zanidatamab in adult patients with HER-2 positive advanced solid tumors? Participants will receive Zanidatamab intravenously on Day 1 of each 2-week treatment cycle. The dosage is 20 mg/kg per cycle.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-20
1 state
NCT07922850
Tailored Nutrition vs. Exercise Prehabilitation Before Colorectal Cancer Surgery
This study will test whether tailored nutritional support before surgery, alone or combined with a structured exercise program, can help adult patients recover better after surgery for colorectal (bowel) cancer. Participants will be randomly assigned to one of three groups: usual care, tailored nutritional support alone, or nutritional support combined with a structured exercise program (multimodal prehabilitation). The main goal is to find out whether either approach improves physical function 30 days after surgery, measured by how far participants can walk in 6 minutes (the 6-minute walk test). The study will also look at nutritional intake, physical function, quality of life, complications, hospital readmissions, and length of hospital stay. A total of 140 adult patients scheduled for surgery for colorectal cancer at hospitals in Northern Norway will be enrolled.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-12
NCT05401318
Tailoring Treatment in Colorectal Cancer
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients. With this, the investigators aim to develop a novel predictive biomarker of immunotherapy response, by testing combinations of chemotherapies and chimeric antigen receptor (CAR) T cells. Critically, this affects a large subgroup of patients currently not considered to benefit from such treatment. To support the hypothesis, the project will make use of cutting-edge, cell-based functional diagnostics. Individual patients' cancer cells will be screened against a panel of chemotherapies and targeted therapies including CAR T cells, to assess the optimal combination of therapies to induce immunotherapy efficacy in otherwise unresponsive CRC.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-12
1 state
NCT02484404
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Background: \- Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growth of cancer cells. This study has two components. In the phase 1 component of the study, researchers want to investigate how well participants tolerate the combination of these drugs in treating advanced solid tumors, and in the phase 2 part of this study, researchers want to study if the combination treatments are effective in ovarian cancer. Objectives: \- Phase 2 part of the study: To determine how effective this combination is in treating ovarian cancer. Eligibility: \- Phase 2 part of the study: Adults age 18 or older with advanced or recurrent ovarian cancer that has no standard treatment. Design: * Participants will be screened with medical history, physical exam, and blood and urine tests. They will have CT or MRI scans. For these, they will lie in a machine that takes pictures of their bodies. * Phase 2 part of the study requests the participants to have tumor samples removed. * Participants will get Durvalumab through an IV. A small plastic tube will be inserted into a vein. The drug will be given every 4 weeks until disease progression. * Participants will take olaparib or cediranib by mouth every day. * Every 28 days will be 1 cycle. For cycle 1, participants will have 2 study visits. All other cycles, they will have 1 visit. At these visits, they will repeat the screening procedures. * Patients will keep a drug and diarrhea diary. * Patients on cediranib will monitor their blood pressure and keep a blood pressure diary. * Participants who can become pregnant, or have a partner who can become pregnant, must practice an effective form of birth control. * After 12 cycles, participants will have 1-3 months of follow-up.
Gender: All
Ages: 18 Years - 99 Years
Updated: 2026-11-10
1 state
NCT07859085
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC). The study consists of a safety run-in period followed by a randomized/expansion period.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-10
NCT07919951
RAPID for Unresectable Colorectal Liver Metastases
The goal of this clinical trial is to learn if the RAPID procedure works to treat colorectal cancer that has spread to the liver and cannot be removed by surgery. It will also learn about the safety of the procedure. The main questions it aims to answer are: 1. How many participants are alive without the cancer progressing or returning 2 years after the first-stage surgery? 2. How many participants complete the second-stage surgery, and how quickly does the liver graft grow between the two stages? 3. What medical problems do participants have around the time of surgery, including serious complications? Participants will: 1. Undergo the first-stage surgery: removal of the left part of the liver and implantation of a small liver graft, with the right portal vein tied off to help the graft grow; 2. Have blood tests and ultrasound checks after surgery, and regular CT or MRI scans to measure graft growth; (4) Undergo the second-stage surgery to remove the remaining diseased liver once the graft has grown enough (5) Visit the clinic every 3 months for up to 2 years after the second-stage surgery for checkups, imaging, and blood tests to see if the cancer has returned
Gender: All
Ages: 18 Years - 70 Years
Updated: 2026-11-05
1 state
NCT07114601
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-04
9 states
NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-04
9 states
NCT07213791
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-04
13 states
NCT07903857
SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study evaluating SND002 Cell Injection in participants with advanced malignant solid tumors that have progressed after standard treatment or for whom no standard treatment is available. SND002 Cell Injection is an investigational product made from a participant's own immune cells (T cells). These cells are collected from a lymph node that drains the tumor, expanded in a laboratory, and then given back to the same participant by intravenous infusion. Because the cells come from the participant, the approach is intended to help the participant's immune system recognize and attack the tumor. The study has two parts. In Part A, small groups of participants receive increasing numbers of cells to identify the dose range that is safest and best tolerated. In Part B, additional participants with colorectal cancer, gastric cancer, or other solid tumors receive the dose range selected in Part A, to learn more about antitumor activity. Before the infusion, participants receive a short course of chemotherapy to prepare the body for the cells. After the infusion, participants receive interleukin-2 injections for several days and are monitored closely. Safety is assessed for 28 days after the infusion, and participants are then followed for up to 1 year to assess tumor response and survival. The main questions are (1) what side effects occur, how severe they are, and what dose range is recommended for further study, and (2) in the expansion part, how many participants experience a reduction in tumor size. Approximately 69 to 78 participants will be enrolled at multiple hospitals in China. Follow-up continues for up to 1 year after the infusion.
Gender: All
Ages: 18 Years - 80 Years
Updated: 2026-11-04
2 states
NCT06663319
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-03
6 states
NCT07913802
Prospective Multicenter Cohort Study of Clinical and Molecular Biomarkers in Colorectal Cancer
This prospective, multicenter observational study aims to identify clinical and molecular biomarkers associated with treatment response, disease recurrence, progression, and survival in patients with colorectal cancer (CRC). Approximately 200 adult patients undergoing surgical resection for CRC will be enrolled and followed for up to five years. Tumor tissue and blood samples will be collected for molecular analyses, and clinical data will be recorded longitudinally to investigate associations between biomarkers and disease outcomes. All treatment decisions will follow standard clinical practice and will not be influenced by study participation.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-03
1 state
NCT06750094
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-03
27 states
NCT06662786
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-03
34 states
NCT01915225
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
Background: \- Recent advances in cancer research have led to new therapies to treat the disease. It is important to continue these advances and discover new ones. To do that, researchers need tissue samples from solid tumors. This study will collect such samples from people already scheduled to have a procedure at the National Institutes of Health Clinical Center (NIHCC). Objectives: \- To collect tissue samples for use in studying new ways to treat tumors. Eligibility: * Adults 18 years and older, with a precancerous or cancerous solid tumor who are scheduled to have surgery or a biopsy at the NIHCC. * Children under the age of 18 but who are older than 2 years of age are eligible to be enrolled on the research sample collection portion of this study if they will have a biopsy or surgery as part of their medical care. Design: * Before their procedure, participants will have a small blood sample taken. * Some participants will undergo leukapheresis. In this procedure, blood is removed through a tube in one arm and circulated through a machine that removes white blood cells. The blood, minus the white blood cells, is returned through a tube in the other arm. The procedure takes 3-4 hours. * For all participants, during the surgery or biopsy, pieces of the tumor and pieces of normal tissue near it will be removed for this study. The rest of the tumor or precancerous growth will be sent to a lab for analysis. * Participants will return to the clinic about 6 weeks after the operation for a routine checkup. Some may have to return for additional follow-up.
Gender: All
Ages: 2 Years - Any
Updated: 2026-10-29
1 state
NCT07895459
MRD Monitoring in Colorectal Cancer Using ctDNA
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy. The objective is to detect minimal residual disease (MRD) early and to predict disease relapse or progression in patients with colorectal cancer (stages II-IV). By monitoring specific KRAS gene mutations (G12 and G13) using the ddPCR method, the study aims to improve risk stratification and treatment response monitoring following primary therapy.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-28
1 state
NCT07896174
Resistance vs Aerobic Prehabilitation Before Colorectal Cancer Surgery
The goal of this clinical trial is to learn which type of exercise before surgery best reduces complications after colorectal surgery in adults with colorectal cancer or precancerous lesions. The main questions it aims to answer are: * Does resistance (strength) training, aerobic (endurance) training, or a combination of both before surgery lower the rate and severity of complications in the first 30 days after surgery, compared with no exercise program? * Which factors influence how well patients follow a prehabilitation program, and does following the program affect surgical outcomes? Researchers will compare three exercise groups with a control group that receives standard care without an exercise program. Participants will: * Be randomly assigned to one of four groups: resistance training, aerobic training, combined training, or no exercise program (control) * Do the assigned home exercise program for 4 to 6 weeks before surgery, with weekly physiotherapy check-ups in person or by phone * Receive nutritional counseling, breathing exercises, and psychological support if needed, regardless of group * Keep a daily exercise diary and record their pulse daily * Undergo physical fitness tests (walking test, sit-to-stand test, handgrip strength) and quality-of-life questionnaires before surgery and 8 weeks after surgery
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-26
NCT01349881
S0820, Adenoma and Second Primary Prevention Trial
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-23
49 states
NCT06403540
The Impact of Laparotomy and Analgesia Methods on Diaphragm
Major abdominal surgeries are traditionally performed via laparotomy. Analgesia is routinely administered during the postoperative period. The goal is to investigate the effects of laparotomy and analgesia methods on diaphragm function.
Gender: All
Ages: 18 Years - Any
Updated: 2026-10-22